TrialHuman vaccines & immunotherapeutics2015

Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.

Nelly Mugo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.